Trials / Completed
CompletedNCT03901729
A Trial to Study BAY1753011 in Patients With Congestive Heart Failure
A Multicenter, Randomized, Parallel Group, Double Blind, Active and Placebo Controlled Study of BAY1753011, a Dual V1a/V2 Vasopressin Receptor Antagonist, in Patients With Congestive Heart Failure: AVANTI Study
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 482 (actual)
- Sponsor
- Bayer · Industry
- Sex
- All
- Age
- 18 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
To assess the efficacy of 30 mg of BAY1753011, with or without furosemide, versus furosemide alone in patients with heart failure and objective evidence of congestion.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BAY 1753011 | Tablet; 30mg or 5mg unit; 30mg once daily in the morning; Oral |
| OTHER | Placebo BAY 1753011 | Tablet; Once daily in the morning; Oral |
| DRUG | Furosemide | Tablet; 40mg unit; 80mg once daily in the morning; Oral |
| OTHER | Placebo Furosemide | Tablet; Once daily in the morning; Oral |
Timeline
- Start date
- 2019-05-29
- Primary completion
- 2021-04-16
- Completion
- 2021-05-21
- First posted
- 2019-04-03
- Last updated
- 2022-04-18
Locations
66 sites across 9 countries: Austria, Bulgaria, Greece, Hungary, Israel, Italy, Poland, Portugal, Spain
Source: ClinicalTrials.gov record NCT03901729. Inclusion in this directory is not an endorsement.